Scholar Rock (SRRK) Q2 Loss Widens 63%
Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company specializing in therapies for serious neuromuscular and rare diseases, released its second quarter 2025 earnings on August 6, 2025. The key news was continued preparation for the potential 2025 U.S. launch of apitegromab, its lead muscle-targeted therapy for spinal muscular atrophy (SMA). The results showed a GAAP net loss per share of $0.98. No revenue was recorded, matching expectations. Overall, the period reflected Scholar Rock’s intense focus on launching its first commercial product, balanced by a rising cash burn and reliance on regulatory approvals.
Source: Analyst estimates for the quarter provided by FactSet.
The company is built around its proprietary platform that targets “latent” forms of growth factors, seeking to offer more selective therapies for neuromuscular and rare diseases. Its lead candidate, apitegromab, is designed as a muscle-targeted monoclonal antibody therapy for SMA, a genetic disorder that leads to muscle loss and weakness. Scholar Rock’s approach aims to improve motor function where current therapies leave treatment gaps.
Source Fool.com
